# A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

> **NCT06615193** · PHASE1 · RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 111 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Refractory Lymphoma
- Relapsed Hematologic Malignancy

## Interventions

- **DRUG:** HDM2005

## Key facts

- **NCT ID:** NCT06615193
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-12
- **Primary completion:** 2026-06-24
- **Final completion:** 2028-02-01
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615193, "A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06615193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*